Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001 Jun 09;357(9271):1850-1
Date
06/19/2001Pubmed ID
11410196DOI
10.1016/S0140-6736(00)04971-0Scopus ID
2-s2.0-0035832529 (requires institutional sign-in at Scopus site) 213 CitationsAbstract
It is not known whether patients with anti-epiligrin cicatricial pemphigoid (AECP) have an increased risk of malignancy. We calculated the expected numbers of cancers in a cohort of 35 such patients based on respective incidence rates for all cancers in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) Registry. Ten patients in this cohort had solitary solid cancers; eight patients developed cancer after onset of AECP (seven within 14 months). The relative risk (RR) for cancer in this cohort was 6.8 (95% confidence intervals [CI]: 3.3-12.5). AECP seems to be associated with an increased relative risk for cancer.
Author List
Egan CA, Lazarova Z, Darling TN, Yee C, Coté T, Yancey KBMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Autoantibodies
Cause of Death
Cell Adhesion Molecules
Cohort Studies
Disease Susceptibility
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasms
Pemphigoid, Benign Mucous Membrane
Risk
Survival Analysis
